Egetis Therapeutics AB (publ) (EGTX) - Total Liabilities
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has total liabilities worth Skr299.30 Million SEK (≈ $32.21 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Egetis Therapeutics AB (publ) to track the company's year-over-year net asset growth rate.
Egetis Therapeutics AB (publ) - Total Liabilities Trend (2008–2024)
This chart illustrates how Egetis Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See EGTX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Egetis Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HomeStreet Inc
NASDAQ:HMST
|
USA | $7.21 Billion |
|
ProCap Acquisition Corp Class A Ordinary Shares
NASDAQ:PCAP
|
USA | $11.39 Million |
|
Anhui Chaoyue Environmental Protection Technology Co. Ltd.
SHE:301049
|
China | CN¥619.40 Million |
|
Soren Acquisition Corp. Class A Ordinary Shares
NASDAQ:SORN
|
USA | $297.17K |
|
VNV Global AB
ST:VNV
|
Sweden | Skr91.18 Million |
|
Exotic Food Public Company Limited
BK:XO
|
Thailand | ฿312.77 Million |
|
Zippy Technology Corp
TW:2420
|
Taiwan | NT$1.69 Billion |
|
SAB Biotherapeutics Inc
NASDAQ:SABS
|
USA | $21.32 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Egetis Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EGTX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Egetis Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Egetis Therapeutics AB (publ) (2008–2024)
The table below shows the annual total liabilities of Egetis Therapeutics AB (publ) from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr299.40 Million ≈ $32.22 Million |
+39.52% |
| 2023-12-31 | Skr214.60 Million ≈ $23.09 Million |
+290.89% |
| 2022-12-31 | Skr54.90 Million ≈ $5.91 Million |
+30.00% |
| 2021-12-31 | Skr42.23 Million ≈ $4.54 Million |
-84.02% |
| 2020-12-31 | Skr264.34 Million ≈ $28.45 Million |
+949.09% |
| 2019-12-31 | Skr25.20 Million ≈ $2.71 Million |
+11.12% |
| 2018-12-31 | Skr22.68 Million ≈ $2.44 Million |
+94.52% |
| 2017-12-31 | Skr11.66 Million ≈ $1.25 Million |
+69.61% |
| 2016-12-31 | Skr6.87 Million ≈ $739.64K |
+58.77% |
| 2015-12-31 | Skr4.33 Million ≈ $465.87K |
-66.21% |
| 2014-12-31 | Skr12.81 Million ≈ $1.38 Million |
+215.75% |
| 2013-12-31 | Skr4.06 Million ≈ $436.60K |
-37.74% |
| 2012-12-31 | Skr6.52 Million ≈ $701.23K |
+67.36% |
| 2011-12-31 | Skr3.89 Million ≈ $418.98K |
+159.12% |
| 2010-12-31 | Skr1.50 Million ≈ $161.69K |
+448.39% |
| 2009-12-31 | Skr273.98K ≈ $29.48K |
-15.32% |
| 2008-12-31 | Skr323.55K ≈ $34.82K |
-- |
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate,… Read more